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less equipotent, although this is not proven by 
randomized trials. In limited disease (LD) an overall 
response COR) rate of 80-95%  and a complete 
response (CR) rate of at least 50-60%  with a median 
survival betw een 12 and 16 months can be achieved, 
Corresponding num bers in extensive disease (ED) 
are an OR rate of 60-80%  and a CR rate of 15-30%  
w ith a median survival betw een 7 and 12 months. 
Thus, despite the high responsiveness to chem o­
therapy, the disease remains ultimately fatal in the 
majority of patients w ith  a 2-year disease-free survi­
val of 15-40%  in LD and 0-5%  in ED pa tien ts / 
Initially, chem otherapy for SGLC was often admin­
istered until death or disease progression occurred, 
In the 1980s it had been questioned w hether 
maintenance chem otherapy could indeed prolong 
survival Comparisons betw een live or six to eight 
and 12 or 28 courses demonstrated that live to six 
courses of chem otherapy gave the same results as 
prolonged treatment, therefore six courses should 
be accepted as a m axim um /""9 Two other large 
Without treatment, median survival in small cell lung randomized trials reported  that three or lour courses
of chem otherapy are probably too short to produce 
long-term disease-lree survival.I0,n
Goldie and Goldman postulated a mathematical 
model concerning genetic resistance at the cellular 
evaluated, and appeared to give higher response level and argued that non-cross-resislant drug combi-
The natural history of small cell lung cancer (SCLC) Is cha­
racterized by early dissemination. Despite the high respon­
siveness to chemotherapy, the disease remains ultimately 
fatal in the majority of patients. One of the strategies to 
improve final outcome is the administration of intensified 
chemotherapy, either by dose escalation or by chemo­
therapy given at shortened Intervals. By now, in only one 
randomized study, in which cyclophosphamide and cispla- 
tln dosage was escalated by 30% in the first course only, a 
survival advantage was demonstrated in limited disease 
patients. The different ways of achieving intensification of 
chemotherapy are highlighted. The addition of growth 
factors in current dose-escalated or accelerated schedules 
seems to result in a relative dose intensity of no more than 
150% when compared to optimally delivered conventional 
regimens. Whether such a moderate degree of dose intensi­
fication will improve survival rates has to be awaited from 
phase 111 trials.
Key words; Chemotherapy, dose intensification 
hematopoietic growth factors, small cell lung cancer.
Introduction
cancer (SCLC) is poor at 5 -12 weeks. In 1969 it was 
reported that cyclophosphamide prolonged the sur­
vival of patients with advanced SCLC,1 In the 1970s 
several combination chemotherapy regimens were
rates and longer survival than single drug therapy.
Nowadays, eye 
tine (CAV), cyelophosphamide/adriamycin/etoposide 
(CDE), cisplatin/etoposide (PE) and (vincristine/) ifios- 
iamide/carboplatin/etoposide (VICE or ICE) are the 
most frequently used combinations. At standard dose 
these combinations are considered to be more or
• — m
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nations should be used in an attempt to circumvcnt 
the developm ent of drug resistance . 12 Several large 
randomized trials evaluated the impact of alternating 
regimens, but could not show any major survival
) j  | |
advantage, ' ‘ ‘ However, in these trials only partial 
non-cross-resistant drugs were used and this may be| ^
insufficient to test the hypothesis.
There is still an on-going debate on the impor­
tance of dose in SCLC treatment. Skipper and
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Schabel showed a clear dose-response relationship of 30-40% in SCLC patients, while complete re­
fer cyclophosphamide and other anticancer drugs in sponses are seldom seen .19 Souhami and colleagues 
animal tumor models, suggevsting that dose is critical showed that in untreated LD patients 1 6 0 -  
to tumor cell kill.16 The concept of dose intensiftca- 200 m g/kg cyclophosphamide, administered during 
tion has been tested in patients with SCLC. Dose one course, produced an OR rate of 84% and a CR
rate of 56%, indicating that there is a clear dose-
20response relationship. These promising results 
between courses. Higher doses per course can be could not be improved by giving a second cycle of
high-close cyclophosphamide, implying that there 
was a quick em ergence of drug resistance.21 Etopo- 
side in a conventional dose has shown response rates 
of 40-60%  in previously untreated SCLC patients,22 
W hen given at a higher dose conflicting data have 
been reported .23” 2*’ O ther agents that do have 
antitumor activity in SCLC have not been studied for
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intensification can be achieved by delivering a high­
er dose per course and/or by shortening intervals
delivered in the first course(s), i.e. early intensifica­
tion, or last course(s), i.e. late intensification, or 
during all courses. In the first part of this paper, we 
will discuss dose intensification studies performed in 
the pre-growth factor period, with attention fo­
cussed on randomized trials. In the second part we 
will review the role of granulocyte colony stimulat­
ing factor (G-CSF) and granulocyte macrophage a _ dose-response  correlation, w hen given as a single 
colony stimulating lactor (GM-CSF) as adjuncts to agent at a megadosage. For etoposide a schedule
dependency has been shown, with increasing activity 
w hen given over several consecutive days,26 which
27may also be the case for cyclophosphamide.
standard-close and intensified chemotherapy.
Before discussing the individual studies, some 
general remarks concerning definitions have to be 
made. The amount of anticancer drugs given during 
a certain time period (m g/m 2 per week or day) is 
referred to as dose intensity (DI) .17 Projected 
(planned) DI is obviously not the same as actually
delivered DI, but the latter, more important, informa- In a meta-analysis it w as concluded that the DI of
Early intensification studies
tion is seldom reported. Another frequently vised 
term is relative DI (RDI), i.e. the ratio of the DI of
the first two courses was not consistantly correlated 
w ith response and survival in SCLC.28 However, in 
the investigated regimen and the DI of another usual this analysis studies in both chemonaive and re­
standard regimen. The average DI for combination lapsed patients w ere  taken together. Dose intensifi- 
chemotherapy is calculated by the sum of Dis of cation studies w ere excluded, because the first two 
each individual agent divided by the num ber of courses would not be  representative lor the whole 
agents in that combination, with the assumption that treatment period. W hen having a closer look at the 
the different drugs are equivalently active, It is tables, it shows that the majority of trials had a RDI 
important to note that the reported DI is often of smaller than 1 (com pared to a reference regimen), 
calculated only for those cycles that are indeed indicating that in the  majority of trials standard 
delivered. This may be misleading, when for exam- versus low dose was compared. Moreover, the range 
pie a substantial number of patients have discontin- of RDIs was small and it may have been difficult to 
ued treatment prematurely, because in these patients assess any correlation at all. The validity of this kind 
the DI may be high, although the delivered total of retrospective analysis has also been questioned by 
dose is actually low, The delivered total dose is others .29 The results of this analysis may therefore 
therefore valuable additional information, bu t this is not be used as an argum ent against dose intensifica- 
often not separately reported, tion studies,
In phase II studies of up-front early intensification, 
megadoses of cyclophospham ide (up to 7.0 g /n r )  
and/or etoposide (up to 1,5 g /n r2) were prescribed, 
with or w ithout autologous bone marrow 
support/ 0^ 4 These regim ens were very toxic and, 
despite promising high CR rates, survival seemed 
not to be improved.
Direct comparisons of chemotherapeutic agents 
at different dosages have seldom been reported in 
Cyclophosphamide is a commonly used agent in SCLC. An old randomized study showed a benefit of
Dose intensification without 
growth factors
Dose-response relationship and 
schedule dependency for single agents 
in SCLC
SCLC. Single-agent cyclophosphamide at conven­
tional dose (1000 m g/m 2) produces a response rate
an increased dose of cyclophosphamide, methotrex-
ate and lom ustine,^  bu t in this study a comparison
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between low and standard dose was made and the 
pivotal question is not w h e th e r  standard dose is 
better than Low dose, but w h e th e r  high dose is 
better than standard dose. To address this question, 
four randomized studies have assessed the im pact 
of early intensification o f com m only used agents 
(see Table l ) / 6-'*9 These trials differ in selection of 
patients, choice of regim en and degree of intensifi­
cation. Patients w ere random ized to receive a num ­
ber of initial courses (1 -4 )  at either intensified or 
standard dose. In the subsequen t cycles all patients 
received courses at standard close. The increase in 
delivered total dose w as relatively larger than  the
encouraging, but may be due to chance, as the 
difference in dose intensity between both arms is 
remarkably small. On the other hand, it may be a 
fact that dose escalation is especially worthwhile in 
LD patients (low volume disease) and this may also 
explain the lack of any benefit in the other early 
intensification studies. Another explanation lor 
these disappointing results may be the num ber of 
patients, that may have been too small to draw 
definite conclusions in three of four trials. Further­
more, the doses of a num ber of drugs were 
increased, although the phase II data of these drugs 
are often incomplete when looking ibr a d o se -
Intensified treatment o f small cell lung cancer
increase in dose intensity. As can be expected, response relationship in SCLC Moreover, the degree 
toxicity was in general m ore severe in the intensi- of intensification may be still too low and mega- 
lied cycles, although this w as manageable. A sig- doses as used in some phase II studies may still be
^  The French trial
nificantly better CR rate by early intensification was 
achieved in only one study, but this was no t 
translated into a better survival, 
was the only trial that show ed an im proved survival 
(2-year survival 43 versus 26% in favor of the 
intensified arm; p  =  0 .02), w ith  a nearly significant 
difference in median duration of CR (540 versus 
358 days; p  — 0 .06).38 This trial was based on a 
retrospective analysis in 131 consecutive treated LD 
patients, which show ed that a 20% increase in
initial closes of cyclophospham ide and cisplatin,
*10produced an increase of 2-year survival of 2 0 % !  
The survival benefit seen  in the French trial is
worthwhile to evaluate in a randomized setting.
Late intensification studies
Norton and Simon proposed a mathematical model, 
in w hich  they argued that small tumors may be less 
sensitive to chemotherapy due to a reduced growth 
fraction. 0 Therefore, they suggested to administer 
intensified chem otherapy of a relative brief duration, 
in case a CR by the induction therapy had been 
obtained. To test their theory a number of small 
phase II trials w ere conducted .12 S1 In most of these
Table 1. Randomized trials comparing identical induction regimens at different dosages in SCLC
No. of 
patients
Standard
regimen
(mg/m2)
No. of HD/ 
total 
courses3
RDI in HD 
course13 (%)
Relative total 
dose (%) in 
HD course0
Grade IV 
neutropenia 
CD/HD (% of 
courses)d
CR
CD/HD
<%)
MST
CD/HD
(months)
Reference
103
LD/
ED
C 1000 
A 50 
V 1
4 /4 C + 47 
A + 1 2  
V - 1 0
C +  56 
A -I" 18
V — 6
45/75* 2 2 / 2 1 12/13 36
298
ED
C 1000 
A 40 
V 1
3/6 AC f  27 C -I-16
A l 6 8
40/79** 1 2 / 2 2 ** 8/7 37
105
LD
C 900 
P 80 
A 40 
E 75 X 3
1 / 6 C I 33 
P -|- 25
23/39 54/67 14/18*• * 38
90
ED
P 80 
E 80 X 3
2/4 PE +  46 PE -f 6 8 2 /32*: * * * 22/23 1 1 / 1 1 39
Abbreviations: C = cyclophosphamide, A =  adriamycin, V =  vincristine, P -  cisplatin, E ~ etoposide. HD ~ high dose, CD ^  conven­
tional dose, RDI = relative dose intensity, CR =  complete response, MST -  median survival time. 
aln both arms four to six courses in total: all courses either CD or the first one to four courses HD followed by CD courses. 
bActually delivered increase in D! in the HD course when compared to CD course (CD ~ 100%), reported per agent or per regimen. 
cActually delivered increase in dose in the HD course when compared to CD course (CD 100%), reported per agent or per regimen. 
dOnly compared for those courses in which HD chemotherapy was prescribed.
* p <  0.003, ** p < 0.05, p = 0*02, p < 0.0001.
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trials only one high-close cycle was given with 
eye I op ho sphamide (4.0—7 .0 g / m 2) and/o r e to p o 8 id e 
(1 —3.5 g /m 2). In 20-50% of patients w ith a partial
II trials, four to seven drugs w ere administered 
weekly in an  alternating fashion over a total of 9 -1 6  
weeks. * In these regimens, most drugs were
response (PR) after induction therapy, a CR after late delivered at an increased DI p e r  course, but in
intensification was achieved, although in general of comparison w ith  conventional schedules sometimes
short duration. In this highly selected patient popu- at the cost o f total dose. The regimens appeared to
lation long-term disease-free survival varied from 5 he feasible in the majority of patients and promising
to 20% and therefore seems not superior to conven­
tional regimens.
In the one randomized late intensification study 
that has been reported by Humblet e t  a l., it was 
assessed w hether after live induction cycles (of six 
different drugs) a last intensified cycle would p ro­
duce better results than an additional standurd-dose 
52 Patients were eligible for randomization in 
case after induction a CR or PR was obtained in LD 
and a CR in ED. This was the case in only 40 of 101 
registered patients; an additional five ED patients 
with PR were abusively also randomized. The last Toxicity w as tolerable in both arms. Grade III and IV
neutropenia occurred  more frequently in the stan-
high response rates were reported. Only two phase 
III trials testing this concept have been reported .56,57 
In the first, 223 patients were randomized to receive 
either the  weekly regimen (cyclophosphamide 
500 m g /m 2, doxorubicin 25 m g /m 2 and etoposide 
120 m g /m 2 in w eek  1, cisplatin 60 m g/m 2 and 
vindesine 3 m g /m 2 in week 2 , vincristine 2 mg and 
m ethotrexate 100 m g /m 2 in week 3; 6 times re­
peated) or six three-weekly courses of CDE (1000, 
50, 3 X 80 m g /m 2, respectively).56 Response rates 
and survival show ed no significant
standard-dose cycle consisted of cyclophosphamide 
750 m g/m 2, etoposide 120 m g/m 2 X 5 orally and 
BCNIJ 60 m g/m 2. In the intensified cycle the doses 
of these three agents were increased by 700, 67 and 
4900%, respectively, with autologous bone marrow 
rescue. After the intensified cycle, the CR rate 
increased from 39 to 79%, while in the standard arm 
the response rate did not increase after the last 
conventional dosed cycle. Although median relapse- 
free survival after randomization was significantly 
better in the intensified arm (28 versus 10 weeks, 
p  — 0 .002), there was no more than a trend toward 
improvement in median overall survival (68 versus
dard arm (59 versus 76% of patients, p  =  0.03). In 
another random ized trial, 438 patients received 
either w eekly chemotherapy (12 alternating cycles 
of ifosfamide 2 g /m 2/doxorubicin 25 m g/m 2 and 
cisplatin 50 m g /m 2/etoposide 2 X 75 m g/m 2) or six 
three-weekly alternating cycles of standard dose 
CAV/PE (600, 50, 2 and 60, 3 X 120 m g/m 2, re­
spectively).57 Again, no differences in response nor 
in survival could be demonstrated. The weekly 
schedule w as less feasible and more often treatment 
had to be reduced  or delayed, with the consequence 
that only 74% of planned DI could be delivered,
55 weeks, ^  =  0 .13), This disappointing result may while 93% of planned DI of the standard regimen 
be explained by the small size of the study, the could be given, In these randomized studies different
inclusion of ED patients and by the fact that during 
late intensification drugs were used that were also 
part of the induction regimen. Patients with a partial 
remission are unlikely to be cured by a last dose 
escalation; however, in this study among four long­
term survivors two were partial responders to the
agents w ere  used in the different arms. Therefore, 
no exact com parisons concerning delivered dose 
and DI can be made. The results of a collaborative 
trial conducted by the Eastern Cooperative Oncol­
ogy Group the  Southwest Oncology Group, and the 
National Cancer Institute of Canada have to be
induction regimen. Despite the support of autolo- awaited. In their study the weekly regimen consist-
gous bone marrow infusion 17% toxic deaths were ing of cisplatin, vincristin, doxorubicin and etopo-
seen during aplasia in the intensified arm, compared side (CODE)55 is com pared with standard dose CAV/
to no toxic deaths in the standard treatment arm, PE. 
and this may also have contributed to the final bad 
outcome. Lastly, no thoracic irradiation was given
and this appeared to be the primary site of relapse Role of growth factors in
in the majority of patients.
Acceleration studies
chemotherapy for SCLC
Growth factors and chemotherapy- 
induced myelosuppression
A third way to increase the DI is delivering chemo­
therapy at shortened intervals. In three phase
Colony stimulating factors are physiologically 
occurring glycoproteins that control proliferation
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I n t e n s i f i e d  t r e a t m e n t  o f  s m a l l  c e ll l u n g  c a n c e r  
and differentiation of m ultipotent and lineage- Growth factors as adjunct to standard-
restricted progenitor cells and, dose chemotherapy
furthermore, p rom ote  the  functional activation of 
mature cells.*58' 62 G-CSF adm inistered s.c. o r i.v. at 
a dose of 0 .3—6 0 /¿g /kg /day  produces a 1.6- to 
12-fold increase in absolute neutrophil c o u n t .63"65 
This increase is dose dependen t, although there is 
a considerable overlap. Alter discontinuation a 
rapid fall in circulating neutrophils to pre-treat­
ment levels is seen w ith in  2 - 4  days. G-CSF 
primarily affects the peripheral counts of neutro­
phils. GM-CSF produces a similar dose-dependent 
increase in neutrophils and produces also a signifi­
cant increase in m onocytes and eosinophils .66’"08 
Both grow th factors p roduce  an increased bone 
marrow cellularity w ith  increased m yeloid-ery- 
throid ratio .60,67,68 G-CSF is associated w ith  only 
minimal toxicity, even at 60 /¿g/kg/day, essentially 
limited to bone p a in ,59,69 In contrast, GM-CSF 
often induces fever, musculoskeletal pain, malaise 
and anorexia. Capillary-leak syndrome and throm-
have been observed at dose levels ofJ1S
30 ¿¿g/kg/day or h ig h e r.^  I n  v i t r o  analyses have 
shown specific liigh-affinity binding sites o f G-CSF 
and GM-CSF to certain SCLC cell lines and some­
times colony forming stim ulation ,70,71 but in  v i v o  The confirmatory trial demonstrated comparable 
a significant effect on tum or cell grow th has ^-79 ^  ... ,
never been  reported.
The augm entation of circulating neutrophils by 
G-CSF and GM-CSF suggested a role in improving 
recovery of myelopoiesis after chemotherapy. In a 
phase II study in SCLC patients, G-CSF was given to 
each patient for 14 days on alternate (odd or even) 
cycles of three-weekly chem otherapy. G-CSF doses 
varied from 1 to 40 /vg /kg/day  and was com ­
menced 24 h after the last chem otherapy
The combination of fever and neutropenia is a life- 
threatening complication of chem otherapy Despite 
immediate administration of broad-spectrum i.v. anti­
biotics, mortality remains approximately '10% among 
patients w ith docum ented infections and 2%  lbr all 
cases of fever.76 The most important prognostic 
factor for the risk of infection is the recovery of 
neutrophil counts ,77 In view of the influence of G- 
CSF and GM-CSF on neutropenia its impact on 
febrile neutropenia has been evaluated in six ran­
domized trials in SCLC], four with G-CSF and two 
w ith GM-CSF (see Table 2).7S_W
In the first, 199 patients were treated by six
7Hcourses of three-weekly CDE. Treatment w ith  G- 
CSF or placebo was given on days 4 -17 , at a dose of 
230 /¿g/m 2. Both severity and duration of neutro­
penia were significantly reduced and, eoncommi- 
tantly, a nearly 50% reduction in incidence of febrile 
neutropenia, in i.v. antibiotic use, hospitalization and 
culture confirmed infections was observed. The 
duration of individual episodes of antibiotic use and 
hospital stay w ere similar in both treatment groups.
results. G-CSF in the weekly CODE regimen 
show ed also a protective effect on number of febrile 
patients and episodes .80 The incidence of infection 
was not reduced during another weekly chem o­
therapy regimen supported by G-CSF, despite higher 
white blood cell counts .81
GM-CSF was studied at different dose levels in 238 
SCLC patients .82 Hematopoeises was stimulated at all 
dose levels, but only patients who received 
10 /¿g/kg GM-CSF required less i.v. antibiotics com­
pared with the observation group. Overall fever 
occurred more frequently in both the 10 and 
normalization of neutrophil count w ithin  2 weeks 20 /fg/kg GM-CSF groups, and this was considered
oe. 63
While on G-CSF, the duration of chemotherapy- 
induced neutropenia was reduced considerably w ith
after day 1 of chem otherapy. This resulted in a 
significant reduction in infectious episodes. GM-CSF 
was evaluated by a similar study design .72
to be a major side-effect of GM-CSF at these dose 
levels. This and other toxicities were the reason lbr 
more patients in the GM-CSF group than in the 
partial abrogation of chem otherapy  induced neutro- observation group to drop out of the study. In the 
penia, GM-CSF failed to reduce the frequency of second GM-CSF trial, the incidence of grade IV 
febrile episodes. In general 5 —10 /¿g/kg/day G-CSF neutropenia was not significantly different, despite 
or GM-CSF is advised w h e n  prescribed for standard- higher neutrophil nadirs in the GM-CSF arm.H* More 
dose chemotherapy. The efficacy of G(M>CSF de­
pends not only on dose but also on schedule of 
administration, At standard chem otherapy, a 7 - 1 0  
day administration starting 1 day after the  end o f 
chem otherapy is optim al in reducing bo th  degree 
and duration of leukopenia. A later onset is less 
effective, an earlier one aggravates leueo- and 
throm bocytopenia .73 ~7 5
important, patients on GM-CSF spent significantly 
more days in the hospital, and had a higher 
incidence of fever, i.v. antibiotic usage, life-threaten­
ing thrombocytopenia, transfusions, toxic deaths 
and non-hematologic toxicities.
In conclusion, there is a remarkable difference in 
the results obtained with G-CSF compared to GM- 
CSF: in three out of four G-CSF studies the incidence
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Table 2. Phase III trials with standard-close chemotherapy evaluating the impact of G(M)-CSF support
No. of Regimen Support Febrile RDI (%) Total dose Reference
patients neutropenia (%)a (%)
199 CDE G-CSF 40* 78
without G-CSF 77
129 CDE G-CSF 26** 96 79
without G-CSF 53 8 8
63 CODE G-CSF 4 4 *** 6 6 b 80
without G-CSF 77 35
40 PE/ID G-CSF NS 84 8 8 81
without G-CSF 82 8 8
238 CDE GM-CSF 5 /¿g/kg 2 1 82
1 0 /ig/kg *j *| ífí $ ît'i
2 0  /¿g/kg 29
without GM-CSF 29
215 PE GM-CSF 75 83
without GM-CSF 2 2 85
Abbreviations: CDE cyclophosphamide, doxorubicin, etoposide; CODE -  cisplatin, vincristine, doxorubicin, etoposide; PE/ 
ID »  cisplatin, etoposide, ifosfamide, doxorubicin; PE =  cisplatin, etoposide. RDI =  relative dose intensity (percent of planned DI). 
Total dose =  percent of planned total dose.
aFor references 78-80: percent of patients with at least one episode of fever; for references 82 and 83: percents of patients requiring
i.v. antibiotics through all cycles.
bNot RDI, but percent of patients whose treatment was completed within 10 weeks (p  <  0.05).
* p < 0,001, :i:* p < 0.002, ***  p < 0.01, ****  p =  0.04
of febrile neutropenia was reduced by almost 50% second study may be due to different patient charac- 
when compared to no support, while conflicting teristics (younger, m ore often limited disease with a 
results were reported w ith  GM-CSF, The absence of better perform ance status). The incidence of fever in 
any benefit in the trial of the Southwest Oncology the observation arm in the GM-CSF study was only 
Group ' may be explained by the concurrent use of 29%, probably due to  the lower CDE dosage (doxor- 
GM-CSF with chest radiotherapy although, on the ubicine 20% and etoposide 33% lower w hen com­
pared w ith  the other two CDE studies),82 
An alternative for prophylactic administration of 
growth factors may be delayed administration of
factors, i.e. not until fever has already 
occurred. The advantage is that overtreatm ent of 
patients that will never have fever will be prevented. 
In the few  studies that have investigated this 
concept, bo th  G-CSF and GM-CSF produced a slightly 
accelerated neutrophil recovery, but this did not 
result in a reduction in duration of fever and
other hand, ameloriation of radiotherapy-induced 
neutropenia by growth factors has also been re­
ported .8*1 Another explanation may be that the 
occurrence of lever was not infection related but a 
side-effect of GM-CSF, because the incidence of fever 
seemed to be GM-CSF dose dependent.82
The incidence of febrile neutropenia is important 
as it is the critical factor influencing cost effective­
ness: the probability of hospitalization would have 
to exceed 40% before the prophylactic use of a 
growth factor will be cost effective. 5 Febrile neutro­
penia after conventional CDE doses is reported to
occur in 6.56% of all cycles.**6 The high rate of
episodes of febrile neutropenia in the first study may 
reflect the unusual vigilant monitoring, a stricter 
definition of febrile neutropenia (i.e. temperature of 
38.2°C or greater and absolute neutrophil count 
below 1.0 X 109/1) and the higher than usual chem o­
therapy dosage (cyclophosphamide 1000 m g /m 2, 
doxorubicin 50 m g/m 2 and etoposide 3 X 
120 m g/m 2). The somewhat lower incidence in the
hospitalization. 87™ 90 A second alternative may be the
prophylactic use of antibiotics. In SCLC patients 
prophylactic co-trimoxazole resulted in a reduced 
overall incidence of docum ented infections of 60% 
w hen com pared  w ith  placebo, especially in case 
neutrophil coun t was less than 100 X 106/L Vr,yl It 
may be w orthw hile  to compare directly the  protec­
tive value of growth factors with that of antibiotics, 
especially from  an econom ic point of view.
The prophylactic  use of growth factors may facil­
itate the delivery of p lanned  chemotherapy dose due
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to less dose reductions and delays, and this was 
indeed demonstrated in two out of four G-CSF 
studies, but only to a m oderate degree (see Table 
2).79,80 Crawford e t  a l . reported no data concerning
78
delivered dose or dose intensities. For GM-CSF 
conflicting observations have been  made. Hamm 
reported that more patients on GM-CSF w ere able to 
receive full-dose cycles (more than  55% of patients 
treated during cycles 2 and 3 w ith e ither 5 or
factors (see Table 3). In the study of Katakami e t  
the MTD was not determined without G-CSF 
and therefore studies with the same chemotherapy 
regimen have been reported in Table 2 : )Z'9* 
Although direct comparison is difficult, a moderate 
dose escalation of carboplatin seems possible with 
the addition of G-CSF. Luikart tried to escalate etopo- 
side dose besides a constant carboplatin dose, but 
this was hardly possible with GM-CSF 10 or
The Cancer and Acute Leukemia10 ¿¿g/kg GM-CSF compared w ith  36% of the observa- 20 /<g/.kg/day» 
tion patients). On the other hand, more patients in Group B reported two separate phase I studies, one
the observation arm w ere able to com plete all six 
cycles (66 versus 60, 42  and 33% of patients w ith  5,
H2
<)7 OHw ithout and one w ith the addition of G-CSF.' ’ 
Despite the use of G-CSF, the MTD was the same
10 and 20 //g/kg GM-CSF, respectively). ~ In the  trial due to the occurrence of febrile neutropenia as the
of concurrent use of GM-CSF and chemoradiotherapy, 
delivered total dose was even 10% lower in the GM-
CSF arm as compared to the  control arm. '
In none of these studies w ere  significant differ­
ences in response or survival found, but as these 
were not primary end-points, sam ple sizes may have 
been too small to detect small differences and this 
outcome may also be explained by the inclusion of 
ED patients.
Growth factors as adjunct to high-dose 
chemotherapy
It has been attempted to increase the maximum
major toxicity. On the other hand, with G-CSF the 
duration of neutropenia was in general brief and 
recycling at a three-weekly interval was, therefore, 
mainly possible in G-CSF-treated patients. The study 
reported  by Paccagnella e t  a l . "  had an interesting 
design. The MTD of epirubicin was determined 
during the first cycle. In the first group of patients 
the MTD was determ ined w ithout GM-CSF and in 
the next group of patients it was attempted to 
increase the MTD by the addition of GM-CSF. The 
MTD could only be moderately increased with the 
addition of GM-CSF, i.e. from 60 to 70 m g /m 2, All 
patients w ere subsequently evaluated for feasibility 
during the next five cycles. Although this was not a 
randomized study, comparisons were made between
tolerated dose (MTD) by the support of g row th  patients treated at a lower epirubicin dose (45
Table 3. Dose-finding studies with and without the addition of G(M)-CSF
Regimen MTD without 
G(M)-CSF 
(mg/m2)
MTD with 
G(M)-CSF 
(mg/m2)
DLT with 
G(M)-CSF
Reference
Carboplatin
Etoposide
500 
3 x  100
92
Carboplatin
Etoposide
350 
3 x  100
93
Carboplatin
Etoposide
450/650a 
3 X 100
thrombocytopenia 94
Carboplatin
Etoposide
3 X 125 
3 X 200
3 X 125 
3 X 250
thrombocytopenia 95
Cisplatin
VM-26
80 
5 x  60
80 
5 X 120
ieukopenia/diarrhoea 96
Cisplatin
Etoposide
3 X 25 
3 X 200
3 X 25 
3 X 200
febrile neutropenia 97, 98
Cisplatin
Etoposide
Epirubicin
60 
3 X 120 
60
60 
3 X 120 
70
neutropenia 99
Abbreviations: MTD = maximum tolerated dose, DLT - dose-II mi ting toxicity. 
a450 at age 70 or older, 650 at age below 70 years.
Antt-Ccincer Drugs < Vof 8  • 1997 555
Growth factors as adjunct to accelerated 
chemotherapy (dose-densified)
60 m g/m 2, without GM-CSF) and at a higher epirubi- 
cin dose (60 -70  m g/m 2, with GM-CSF). It was 
demonstrated that the higher close with GM-CSF was 
not only feasible, but that GM-CSF also had reduced 
significantly the severity of neutropenia w hen com ­
pared to patients treated at a lower epirubicin dOvSe 
without GM-CSF (grade IV neutropenia 26 versus 
57%, /;< ().()!). In patients on GM-CSF, neutropenia 
in the first course (in which MTD was determined) 
was more severe than in the next five courses, Due 
to less dose reductions and delays for hematological 1000 m g /m 2, doxorubicin  50 m g /m 2, vincristine 
toxicity, the actually delivered DI of epirubicin over 2 mg on day 1; cisplatin 60 m g /m 2 and etoposide 
six cycles was in the GM-CSF-treated patients sub- 150 m g /m 2 on  days 8 and 9).100 In the  first five 
stantially increased by 63% when compared to patien ts GM-CSF w as given as soon as grade IV 
patients treated without GM-CSF, This resulted also leukopenia  developed, while in five additional pa­
in an increase of relative dose intensity for cisplatin tients the  sam e regim en was given w ithou t GM-CSF 
and etoposide of about 30%, despite the same Although n o t one patien t was indeed able to receive 
planned dose for these two agents. Moreover, only the p lan n ed  weekly regimen, the average num ber of 
73% of planned cycles could be delivered in the 
control arm versus 86% of cycles supported by GM- 
CSR Patients treated at lower dose levels had an OR
VCG Tjan-Heijnen et ill,
The feasibility of reducing intervals be tw een  full- 
p lanned-dose chem otherapy courses by the addition 
of G(M)-CSF has been  tested in a few  phase II 
studies (see Table 4). Ardizzoni e t  a l. reported  such 
an ‘acce le ra ted ’ chem otherapy regimen of CAV 
and PE, w h ic h  w as p lanned  to be alternated weekly
lbr a total of six courses (cyclophosphamide
2
days requ ired  to recycle was substantially reduced 
w h en  com pared  to the standard interval of 21 days 
(10 days w ith  and 13 days without GM-CSF). As a 
rate of 72% (CR 24%), compared to an OR rate of co n seq u en ce  treatm ent duration was limited to 57 
95% (CR 40%) in patients treated at higher dose 
levels.
days w ith  GM-CSF and 73 days w ithout GM-CSF 
(standard p ro jec ted  107 days), resulting in an almost 
In conclusion, in these few studies in SCLC it was 2- and  1.5-fold increase in dose intensity, respec- 
shown that the MTD could not or only modestly be tively. A lthough the  decrease in treatm ent duration
in patien ts treated  w ith  GM-CSF was larger than 
w ithou t GM-CSF, it w as disappointing that the 
over all courses could be increased by 30-60%  in absolute benefit o f GM-CSF was not as large as 
one phase II study. More studies are warranted in expected . T he authors suggested, that the  ‘prophy- 
order to assess the exact role of growth factors in lactic’ use o f grow th factors may be m ore suitable 
chemotherapy dose, instead o f 'on-dem and’ use. Over all cycles, the
increased by the addition of G(M)-CSF. Nevertheless, 
due to less dose reductions and delays, the total RDI
Table 4. Standard-dose chemotherapy delivered at shortened intervals with the addition of G(M)-CSF
Regimen No. of 
patients
Mean interval 
(range) 
(days)
Percent of 
patients that 
completed 
four/six cycles
Grade IV WBC 
(% of cycles)
Grade IV 
platelets 
(% of cycles}
RBCa 
(no. of 
patients)
PLTb 
(no. of 
patients)
Reference
CAV/PE
GM-CSF
5 10(6-19) 80/80 3 2 100
CAV/PE 5 13 (6-23) 100/100 3 0 100
CDE
GM-CSF
15 17 (13-22) 87/40 22 19 9 5 101
CDE
G-CSF
32 17(14-30) 81/63 21 5 102
CDE
G-CSF
20 17(14-42) 65/60 40 25 17 12 103
Regimen: see text
aNumber of patients that received red blood ceil transfusions 
bNumber of patients that received platelet transfusions
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mean white blood cell coun t and platelet nadirs 
were 0.60 and 4 6 X 1 0 9/1 in the GM-CSF group 
versus 0.84 and 105 X I 0 l)/ l  in the controls, p rob­
ably reflecting the higher DI in the GM-CSF-treated 
patients. The increase in DI was not associated w ith
chem otherapy at shortened intervals. 
However, the exact role of growth factor addition 
should preferably be determined in a randomized 
fashion and for this reason 65 patients were rando­
mized to receive VICE (ilbsfamide 5 g /m 2, carbopla-
Intensified treatment o f  small cell lung cancer
a worsening of non-hematological side-effects. In a tin 300 m g/m  , etoposide 120 m g /m 2 on day 1 and 
subsequent trial, the same group  tried to accelerate 
standard CDE (cyclophosphamide 1000 m g /m 2, dox-
2 , and 240 m g/m " on day 3 orally, vincristine 2 mg) 
w ith or w ithout G-CSF,106 There was not a lixed 
treatm ent interval planned to maximize DI in both 
treatm ent arms in order to determine the exact 
contribution of G-CSF Retreatment was possible as 
soon as WBC count was 3*0 X 109/1 or greater and 
platelet count was 100 X 109/1 or greater. No dose 
reductions were allowed. It was demonstrated that 
in both arms dose intensity could be increased 
compared to the conventional four-weekly schedule: 
over the first three cycles RDI was 1.34 for the G- 
300 //g/day day 4 -1 4  in 32 p a tien ts111* and lenogras- CSF arm and 1.17 for the control arm ( p  =  0.001).
Over all six cycles the average RDI was 1.25 and 
1.18 per cycle, respectively ( p  =  0.03). When both 
arms w ere compared among each other, it was
orubicin 45 m g /m ,  etoposide 3 X 100 m g /ir r )  by 
giving it every 2 weeks w ith  prophylactic GM-CSF 
10//g /kg /day  from day 4 to 13 .10 The Medical 
Research Council (MRC) Lung Cancer Working Party 
performed two comparable studies with CDE, but 
the chemotherapy was adm inistered at a m oderate 
higher dose for two agents (doxorubicin 50 m g /m 2 
and etoposide 3 X 120 m g /n r2) ,102,103 Moreover,
they prescribed G-CSF instead of GM-CSF (filgrastim
102
tim 5 /ig /kg/day day 4 -14  in 20 pa tien ts103). The 
mean chemotherapy interval was 17 days for all 
three studies. Ardizzoni calculated that the delivered
RDI was 1.44 per cycle. It must be rem em bered that shown that only the first two intervals were shor-
RDI and intervals can only be calculated over cycles 
that are actually delivered. Approximately 80% of 
patients were able to receive at least four cycles, but 
only 55% were able to c o m p l e t e  all six cycles. 
Premature discontinuation in all three studies was 
mainly due to progressive throm bocytopenia and 
anemia, particularly severe after the fourth cycle. 
This was also the main reason for delays, w hich 
were concentrated towards the end of the treatment 
period. In the MRC studies grade IV neutropenia 
occurred more often than in the study of Ardizzoni, 
probably due to the higher doses per course. Never­
theless, neutropenia had almost invariably resolved 
by the end of the 14 day period  in all three studies
tened by 2 -3  days in the G-CSF arm. Thus, the 
contribution of G-CSF to dose intensity was rather 
disappointing, despite its statistical significance 
(1 .25/1.18 X 100% =  4-6%), Fifty-five percent of pa­
tients com pleted six cycles in both arms. Neutrophil 
counts w ere consistently higher in G-CSF patients, 
but in both arms 70% of patients had at least one 
period of febrile neutropenia. There were more 
toxic deaths in the G-CSF arm (6 versus 1), Response 
rates w ere similar, but 2-year survival was better in 
the G-CSF arm (32 versus 15%), although 32% is not 
better than usually reported in good prognosis 
patients.
In conclusion, standard chemotherapy can be
and there was no evidence of increasing risk of accelerated both with and without growth factor
neutropenia following subsequen t cycles. Non-hema- 
tologie toxicity was in general mild and manageable.
support, simply by giving chemotherapy as soon as 
blood counts are recovered. The magnitude of 
Toxic deaths occurred in approximately 10% of acceleration depends on the degree of myeiosup- 
patients in all three studies. Response rates in the pression produced by a specific regimen. G-CSF 
MRC] studies seemed similar to conventional regi- seems to improve DI by no more than 10 30%
mens. In conclusion, accelerating CDE is feasible but 
only for a limited (four) num ber of cycles, thereby 
compromising delivery o f total cumulative dose as 
projected in standard three-weekly regimens of six 
courses. A fifth acceleration study has been reportedI Q A
only in abstract form. The authors concluded that
w hen  compared to a maximalized standard-dose 
regimen. It should be noted that increased DI seems 
only feasible for the first lour courses due to 
cumulative thrombocytopenia and anemia. As a 
consequence total dose in a intensified regimen may 
even be lower than in a conventional regimen. At
the combination of epirubicin 80 m g /m 2 and ifosfa- present it is unclear w hether total dose or DI is the
mide 5 g /m 2 could be given at two-weekly instead 
of three-weekly intervals due to the addition of G- 
CSF. No details concerning actual mean interval were 
given.
most important param eter for final outcome. For this 
reason several collaborative groups have initiated a 
num ber of randomized trials. The EORTC has started 
a study, in w hich three-weekly CDE is compared
These phase II studies su p p o rt the feasibility of with two-weekly CDE which is supported with G-
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CSF, In this study standard CDE is given for live chem otherapy cycles were prescribed (etoposide, 
courses, while the accelerated CDE is given for only 
four courses at an approximately 25% higher dose 
per course. By this design the total dose will be 
equal in both arms, while in the accelerated arm the 
treatment will be delivered in half the time in 
comparison with the standard arm. The influence of 
the 100% dose increase on  survival and response 
will be evaluated,
VCG Tjan-Heijnen et al.
Growth factors and peripheral blood 
progenitor cells
ifosfamide, cisplatin and epirubicin) followed by 
one 2 h leukapheresis procedure after the second 
course .115 Subsequently one high-dose course 
(300% of the conventional schedule, with the 
replacem ent of cisplatin by carboplatin) was admin­
istered and this showed to be feasible with PBPC 
infusion. However, if cure is the goal to be 
achieved, more than one high-dose cycle is prob­
ably needed. Shea e t  a l. demonstrated that multiple 
courses of high-dose chemotherapy were feasible 
by the repeated administration of PBPC,1,6 In SCLC 
one study has reported the sequential administra-
tion of PBPC.,  117 Twenty-five SCLC patients were
We have discussed the influence of G(M>CSF on treated w ith six cycles of ICE with G-CSF 300 fig  
peripheral neutrophil counts. An additional effect is on days 4 -1 5 . PBPC were collected during each 
a pronounced dose-related increase in peripheral cycle on day 15, by leukapheresis in cohort 1 
blood progenitor cells (PBPC), not only including (cryopreservation) and 2 (stored at 4°C), and by
venasection in cohort 3 (500-750  ml whole blood 
stored at 4°C), and reinfused on day 3 of the next 
cycle. Patients in cohort 1 were treated every 3
gran ulocyte macrophage colony
but also erythroid and megakaryocyte 
KKU07 ^ jie meciiailisms by which cytokincsCFCs.
increase PBPC are not well understood. Proliferation weeks, and in cohorts 2 and 3 every 2 weeks. ICE 
resulting in expansion of the population of progeni- chem otherapy with G-CSF was effective in mobiliz-
tor cells, differentiation of stem cells into circulating ing blood progenitors, with a median of 120-fold
progenitor ceils and an alteration in adhesion mole- above baseline. The planned DI was 134% for
cules on the cell membrane that regulate the release
of cells from the marrow into the peripheral blood
108may all play a role; Initially, PBPC were only used
cohort 1 and 200% for cohort 2 and 3. This could 
indeed be delivered in the first three cycles, blit 
only half of patients in cohorts 2 and 3 completed
together with AMBT. It was demonstrated before all six courses, compared to two-thirds in cohort 1.
that the application of growth factors after ABMT 
resulted in an accelerated neutrophil recovery, when
109
Toxicity was not significantly different between the 
th ree  cohorts, The authors concluded that PBPC 
compared to ABMT alone.,wv The addition of PBPC collected in whole blood without cryopreservation 
could not further accelerate neutrophil recovery, but is a practical and attractive procedure in chemo- 
platelet recovery was remarkably faster than in therapy regimens of short duration, using drugs of 
controls.110 The use of PBPC may therefore facilitate short half-life that are effective in mobilizing blood
much larger dose-intensificatlons than achieved by progenitors and have low toxicity for blood stem
G(M>CSF or by ABMT Another theoretical advantage cells. The group has opened a phase III study with
of PBPC over ABMT may be the lower risk for tumor the  cohort 3 schedule as the investigational arm.
cell contamination, although concomitant tumor cell
recruitment upon mobilization of PBPC has been
demonstrated in ED SCLC patients.111 The biologic DlSCllSSion
relevance of this observation is not completely
understood. To mobilize PBPC, G(M)-C8F can be 
used either alone or in combination with high-dose
It is apparent that we need better chemotherapy for 
SCLC, considering the fact that the majority of
cyclophosphamide or disease-specific chemotherapy patients will ultimately die of their disease. One 
By the combination of a growth factor and chemo- approach to improve outcome may be the delivery 
therapy an even higher num ber of PBPCs can be of chemotherapy at increased dose intensity, either 
collected, thereby reducing the num ber of necessary 
leukaphereses.112,113 Not all regimens are equally 
effective in mobilizing PBPC. It was demonstrated 
that PE produced a 10-lbkl increase of PBPC, 3 -5
weeks after treatment, while no rebound phase
1  t |
occurred after CAV treatment. ‘ In a phase II study
by dose escalation for one or more cycles or by 
giving chemotherapy at shortened intervals. Both 
concepts have been evaluated in SCLC patients. By 
giving chemotherapy at shortened intervals the 
delivery of total dose may be compromised. At 
present, it is unclear whether dose intensity or total
in 18 LD patients, G-CSF plus tw o conventional-dose dose is the most important parameter for final
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outcome and both factors should therefore be 
evaluated separately in future trials.
Despite promising phase II data concerning mega­
dose chemotherapy, a survival benefit was seen in 
only one out of four random ized early-escalation 
studies (in LD patients).36 39 In the one randomized
late-escalation trial in SCLC, the relapse-free survival 
after randomization w as significantly better after one 
high-dose cycle, but there  was no m ore than a trend 
toward improved m edian overall survival.52 In tw o
higher dose equivalent in activity to cyclophospha­
mide. In soft tissue sarcoma high-dose ifosfamide 
was demonstrated to circumvent the resistance to 
standard-dose ifosfamide, while at this dose treat­
m ent was still manageable using routine clinical
1 IBsupport. For etoposide the dose-response data
:r pcw eiinicivl studies have related
A
Intensified treatment o f  small cell lung cancer
are c
iivexposure of doxorubicin to antitumor effect, 
major problem for significant dose-escalation is 
cardiotoxicity, which is the most important chronic
reported phase III acceleration studies no survival dose-limiting toxicity. The analog epirubicin* w hen 
benefit was demonstrated; however, in both studies compared with doxorubicin, causes less myelo- and
dose intensity was not the sole variable, w hich
^  / j  O T  É M
precludes definite conclusions. *’ O ne explanation
cardiotoxicity, thus allowing dose intensification. 
vSuch dose-intensive regimens of epirubicin have
of these disappointing results may be the relative produced high response rates in a num ber of
small size of most of these trials. Furthermore, a 
survival advantage in some patients may not have 
been demonstrated due to the inclusion of patients 
likely to have a less favorable outcom e (like ED 
patients). Moreover, the  schedules investigated may
malignancies including SCLC,99,120 Cisplatin is an­
o ther important drug in SCLC. The dose of cisplatin 
can be increased to 200 m g /a r  every 4  weeks, but 
further dose escalation is limited by cumulative 
neurotoxicity.121 Although high-dose cisplatin
not have been the m ost suitable ones, i.e. type of seemed promising in several phase II studies, it was 
intensification, num ber of intensified cycles and recently demonstrated that with 200 m g /m 2 per
choice of agents.
It is important to reconsider the two ways to 
achieve intensification; ( 1) escalation and (2) accel­
eration. Although these tw o approaches may seem 
comparable as they are bo th  being used to increase 
dose-intensity, the underlying mechanisms of their 
action are probably quite different. This distinction
course no survival advantage was seen in non-SCLC 
and poor-risk germ cell tumors.122,123 As noted 
earlier, in a randomized trial in SCLC dose escalation 
of both cisplatin and cyclophosphamide w ith ap­
proximately 30% for one course only, resulted in a 
significant survival benefit; This observation re­
mains difficult to interpret and needs to be con-
is often not recognized and bo th  approaches are firmed before any conclusion can be made.
Carboplatin is the most important cisplatin analog, 
Significant dose escalation may overcome intrinsic and is less nephro-, neuro* and ototoxic when given
*
frequently mixed up in the literature.
drug resistance, w hich  can be proven  by a response 
after high-dose chem otherapy, not seen after the 
same chemotherapy at standard dose, The efficacy 
of high-dose chem otherapy  was initially dem on­
strated in patients w ith  acute myeloid leukemia, 
Iiigh-dose chem otherapy was not yet able to in­
crease survival in SCLC, but the doses in the phase 
III trials were substantially lower than the megadoses 
in the earlier (promising) phase II trials. I j i  more 
recent years high-dose chem otherapy has
increasingly used w ith  the support of PBPC, and 
growth factors, in different solid tumors like breast 
cancer and germ cell tumors. By now, it is not
known how many high-dose cycles are needed, but 560 m g /n r) .
at a conventional dose. The major side-effect is 
myelosuppression, especially thrombocytopenia. It is 
one of the most frequently used agents in high-dose 
schedules, often in combination with high-dose 
cyclophosphamide and thiotepa, of which the phase 
II results are encouraging. However, in patients with 
advanced (relapsed and previously untreated) ovar­
ian carcinoma, it was demonstrated that, although 
the likelihood of tumor response increased with 
higher carboplatin dose, this relationship was non­
linear and did not increase significantly above a 
carboplatin area under the curve (AUC) of 
7 mg/nil X min (more or less comparable with
Methotrexate and 5-fiuorouracilK  12-i,I2*i
it is in general believed that it should be more than are both antimetabolites with increased activity at a
one cycle. The use of very high-dose chemotherapy higher dose, but these two agents do not play a
is only logical for those agents that have a S-shape major role in the treatment of SCLC. Significant dose
dose-response curve of w hich  the plateau level has escalation of vincristine is restricted by cumulative
not yet been reached. Cyclophospham ide has been neurotoxicity. Adequate high-dose studies with new
demonstrated to p roduce  a 3-fold increase in re- antineoplastic agents, like the taxanes and topo-
sponse rate at a 7-fold increase in dose above 
standard. Ifosfamide is at an approximately 4 times
isomerase I inhibitors, have to be awaited.
By the second approach, i.e. giving chemotherapy
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at shortened intervals, efficacy may be increased by 
preventing tumor regrowth during the intervals and 
also by preventing the development of intrinsic drug 
resistance during the interval. This approach may be 
especially worthwhile for tumors like SCLC, that are 
characterized by rapid growth and marked chemo- 
sensitivity. This application may also be useful for 
drugs that are already at their maximum response 
level.
It is obvious that substantial dose intensification is 
only possible for those anti-cancer drugs that have 
myelosuppression as main side-effect. In the older 
intensification studies autologous bone marrow 
transplantation was used as rescue, but this proce­
dure was still accompanied with a significant degree 
of morbidity and mortality Because G-CSF and GM- 
CSF are able to reduce duration and severity of 
neutropenia, it was suggested that the delivery of 
intensified chemotherapy supported by these factors 
might be more feasible. However, the addition of 
growth factors in current dose-escalated or acceler­
ated schedules seems to result in a relative dose 
intensity of 110 more than 150% when compared to 
optimally delivered conventional regimens. At this 
point cumulative thrombocytopenia becomes a ma­
jor problem. With the sequential administration of 
peripheral blood progenitor cells repeated cycles at 
200% RDI can be delivered; at this level both 
hematologic and non-hematologic toxicity become 
dose limiting. Whether such a degree of dose 
intensification will improve survival rates has to be 
awaited from phase III trials. However, w hen reduc­
tion of neutropenia and/or febrile neutropenia will 
remain the most important effects of these hemato­
poietic growth factors, prophylactic administration 
of antibiotics as adjunct to standard-dose chemo­
therapy or application of chemotherapy dose reduc­
tions or delays may be more appropriate,
VCG Tjan-Heijnen et al.
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